Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Does The Orphan Drug Act Need A Facelift? Advocates Consider Changes

Executive Summary

Rare disease advocates are wondering whether it may be time to strengthen the Orphan Drug Act and at least one organization is researching potential improvements that could be made to the pathway.

You may also be interested in...

Orphan Drug Prices To Face Fiscal Cliff Scrutiny, NORD Expects

If the debate does include a focus on entitlement spending, NORD does not plan on taking sides.

NORD Says Orphan Drug Act Is Fine As Is, Wants To Work For Improvements Within System

The group is afraid asking for wholesale changes to the law would invite too many problems, VP Dorman says at BIO.

Orphan Drugs Need Easier, Speedier Approval, Not More Exclusivity, CEO Says

Advocates and drug developers continue to call for an Orphan Drug Act renovation – not to add more years of marketing exclusivity, but to consider allowing easier and cheaper development programs.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts